Late Breaking Abstract - Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO - Amsterdam 2025

ALERT 1: obstructive airway diseases in children and adults

Chair(s): James D. Chalmers, Antonio Spanevello, Raffaella Nenna, Darren Taichman, Ozge Yilmaz

Session type: Clinical trials session

Late Breaking Abstract - Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO

Neil Greening

EVENTS HOME

Previous presentation

Next presentation

Session content

RCT Abstract - Paracetamol compared to ibuprofen as required for pain or fever: One-year outcomes for eczema and bronchiolitis in the PIPPA Tamariki RCT

Stuart Dalziel

Replay

Abstract

Slides

RCT Abstract - Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial

Lee Hatter

Replay

Abstract

Slides

RCT Abstract - Conservative versus standard oxygen saturation thresholds in children with acute respiratory distress: a multicentre randomised controlled trial (OxyKids).

Sam Louman

Replay

Abstract

Slides

Wrap-up by discussant and discussion

Ozge Yilmaz

Replay

Slides

Efficacy and Safety of Dupilumab (DUP) vs Omalizumab (OMA) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with Asthma (EVEREST study)

Enrico Marco Heffler

Replay

Abstract

Slides

RCT Abstract - Budesonide/glycopyrronium/formoterol fumarate dihydrate triple therapy for inadequately-controlled asthma: KALOS and LOGOS study results

Alberto Papi

Replay

Abstract

Slides

Late Breaking Abstract - Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO

Neil Greening

Replay

Abstract

Slides

Wrap-up by discussant and discussion

Antonio Spanevello

Replay

Slides

Session aims

The ALERT sessions (Abstracts Leading to Evolution in Respiratory Medicine Trials) showcase important and very late-breaking clinical trial data from all respiratory disease areas. Presenters, discussants, session chairs and the audience will actively discuss the showcased trials.

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}